Company / Capital Expenditures
Phio Pharmaceuticals Corp. Capital Expenditures History
FY2012-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$72.0K
FY2020
5-year range
$4.0K / $203.0K
FY2016-FY2020
Trend
+1340.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +1340% YoY in FY2020, a notable deviation from the 6-year average annual change of +1067%.
Based on SEC 10-K filings.
$72,000 in FY2020 with a 3-year CAGR of +162.1%.
Declined from $203,000 to $72,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +162.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +162.1%, indicating consistent growth.
- In FY2020, capital expenditures increased 1340.0% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.94 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $72.0K | +1340.0% |
| FY2019 | $5.0K | -97.5% |
| FY2018 | $203.0K | +4975.0% |
| FY2017 | $4.0K | -93.0% |
| FY2016 | $57.0K | +280.0% |
| FY2013 | $15.0K | +0.0% |
| FY2012 | $15.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026